ArborGen Holdings Limited (NZX: ARB) has announced revised guidance for US GAAP EBITDA for FY22 due to the continuing disruptions from the COVID-19 pandemic.
The Company is expecting US GAAP EBITDA in the range of US$9.5 to US$10.5 million and is tracking higher Mass Control Pollinated (MCP®) sales than the previous year.
See more
